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  This study was performed to evaluate the sedative and 
analgesic  effects  of  xylazine  (X)  and  tramadol  (T) 
intravenously (IV) administered to horses. Six thoroughbred 
saddle horses each received X (1.0 mg/kg), T (2.0 mg/kg), 
and a combination of XT (1.0 and 2.0 mg/kg, respectively) 
IV.  Heart  rate  (HR),  respiratory  rate  (RR),  rectal 
temperature (RT), indirect arterial pressure (IAP), capillary 
refill time (CRT), sedation, and analgesia (using electrical 
stimulation and pinprick) were measured before and after 
drug administration. HR and RR significantly decreased 
from  basal  values  with  X  and  XT  treatments,  and 
significantly increased with T treatment (p ＜ 0.05). RT 
and IAP also significantly increased with T treatment (p 
＜  0.05).  CRT  did  not  change  significantly  with  any 
treatments.  The  onset  of  sedation  and  analgesia  were 
approximately  5  min  after  both  X  and  XT  treatments; 
however, the XT combination produced a longer duration 
of sedation and analgesia than X alone. Two horses in the 
XT treatment group displayed excited transient behavior 
within 5 min of drug administration. The results suggest 
that  the  XT  combination  is  useful  for  sedation  and 
analgesia in horses. However, careful monitoring for excited 
behavior shortly after administration is recommended.
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Introduction 
Sedatives and analgesics have been widely used for 
diagnostic procedures and minor surgery in standing 
horses [10]. The sedative agents contain alpha-2 
adrenergic receptor agonists (α2 agonists), phenothiazines, 
and benzodiazepines. The analgesic agents are comprised 
of opioids, α2 agonists, and non-steroidal anti- 
inflammatory drugs [10]. A veterinarian may choose a 
drug based on the temperament and physical status of the 
patient, procedure to be performed, available facilities, 
drug cost, and/or personal preference [5,10]. Combinations 
of these drugs have been shown to provide more desirable 
sedation and analgesia, and decreased side effects than 
when the drugs are used individually [3,5,10].
The α2 agonists available for horses include xylazine (X), 
detomidine, romifidine, and medetomidine; they are used 
for sedation, analgesia, and muscle relaxation [5]. The 
clinical and cardiopulmonary effects and other complications 
associated with these drugs are well-known [5,9,10,12,17, 
20]. Although their principle actions and side effects (e.g., 
bradycardia, second degree atrioventricular block, respiratory 
rate decrease, and ataxia) are similar, there are some 
differences in the duration, degree of action, and 
complications related to these drugs [5,12,17,20] e.g., the 
duration of detomidine and romifidine is longer than that of 
X, and romifidine produces less lowering of the head and a 
lower degree of ataxia than the other drugs [5,6,12]. 
Medetomidine is not widely used in equine practice because 
it produces more pronounced and prolonged ataxia [1,5, 
20]. 
Opioid agents, primarily used for their analgesic 
properties in small animal practices, are of limited use in 
equine practice because of the possibility of central 
nervous system (CNS) excitation [2,10]. However, opioids 
are often used with α2 agonists, the combination of which 
increases clinical effects and decreases side effects, 
compared to the individual use of the drugs [3,5,10]. 
Opioids used in horses include morphine, butorphanol, and 
buprenorphine [2,3,10]. Mu-agonist opioids are generally 
considered as the most effective analgesics. In horses, 
however, the μ-receptor antagonist and κ-agonist opioid 
butorphanol is most commonly used [5,10]. These drugs 
are subject to legal control in most countries. 
Tramadol (T), a centrally acting analgesic drug that is a 
synthetic analog of codeine, is not a controlled drug in 
Korea [16,18]. For the last two decades, T has been used in 
humans to treat moderate to severe postoperative pain [18]. 282    Jong-pil Seo et al.
More recently, T was introduced into veterinary medicine, 
and has shown analgesic effects in mice, rats, dogs, and 
cats [11,15,16]. T is also a potential analgesic agent for 
horses, although there is a paucity of studies addressing its 
use in this species. 
The objectives of this study were to evaluate the sedative 
and analgesic effects of T in horses and to compare the 
clinical effects of the combination of XT with the 
individual drug effects.
Materials and Methods 
Experimental animals
Thoroughbred saddle horses (four mares, one stallion, 
and one gelding), 3- to 7-years-of-age (4.6 ± 1.8 years), 
weighing 440 ± 27 kg (399∼470 kg) were used for this 
study. The horses were housed in individual stalls at a 
riding club near the College of Veterinary Medicine, Seoul 
National University (Korea) where they were fed hay and 
concentrates and permitted free access to water. Before the 
experiment, informed owner consent was obtained.
Procedures
The experiment was performed as a randomized, blind, 
three-way crossover design with at least a 7-day washout 
period between treatments. Prior to each treatment, the 
horses were physically examined and weighed. Food, but 
not water, was withheld for at least 8 h prior to drug 
administration. During the experiment, horses were placed 
in stocks and allowed 20 min to acclimate to their 
surroundings. The hair over the left jugular vein was 
clipped, and a 16 gauge over-the-needle catheter was 
placed in an aseptic manner. The left paralumbar fossa 
region was aseptically prepared with 70% alcohol, and two 
20-gauge, 1.5 inch needles were inserted 7 cm apart for 
analgesic effect assessment. The electrical stimulator was 
placed at least 2 m away from the horses. Electrocardiogram 
pads for apex-base lead, rectal temperature (RT) probe, and 
indirect arterial pressure (IAP) probe at the base of the tail 
for oscillometry were positioned for data collection. 
Treatments consisted of X (Xyzine 300; SF, Korea), 1.0 
mg/kg; T (Toranzin 50; Samsung Pharm, Korea), 2.0 mg/ 
kg; or a combination of XT 1.0 and 2.0 mg/kg respectively 
administered intravenously (IV) via a jugular vein catheter. 
X was given as a bolus, whereas T was slowly injected over 
at least 2 min. For the XT treatment, the X bolus was 
followed by a slow T injection. Heart rate (HR), respiratory 
rate (RR), RT, IAP, capillary refill time (CRT), sedation, 
and analgesia (using electrical stimulation and pinprick) 
were measured prior to drug administration and 5, 10, 15, 
20, 25, 30, 40, 50, 60, 75, 90, 105, and 120 min after 
administration. HR, RT, and IAP were measured using a 
BSM-2301 patient monitor (Nihon Kohden, Japan). RR 
was evaluated by counting thoracic wall movements for 1 
min. CRT was determined by pressing a finger against the 
horse’s upper gums for 2 sec and monitoring color change. 
Degree of sedation was quantified using a 4-point criteria 
system in which (1) denoted deep sedation, defined as 
markedly decreased movement, lower head carriage with 
mouth to the carpal joint, marked drowsiness, droopy 
eyelids and lip, and markedly wide based stance; (2) 
denoted moderate sedation, defined as moderately 
decreased movement, lower head carriage with mouth to 
the elbow joint, drowsiness, slightly droopy eyelids and 
lip, and moderately wide based stance; (3) denoted mild 
sedation, defined as slightly decreased movement, lower 
head carriage with mouth to the shoulder, and decreased 
sensitivity to surroundings; and (4) denoted no sedation, 
which was considered to be normal behavior and appearance. 
Analgesic effect was assessed by two methods: the first 
was electrical stimulation (5.5 mV, 1 Hz, 1 sec) on the left 
paralumbar fossa with an electrical stimulator (AM-3000, 
TEC, Japan); and the second was by pinprick with a 20- 
gauge, 1.5 inch needle on the right neck, right paralumbar 
fossa, and right hip, which were pricked one by one. 
Needle prick was continued to the whole length of needle 
(1.5 inches), but applied just once in only one place. The 
degree of analgesia was assessed by observing the changes 
from baseline in responses (i.e., attention to the stimulated 
site, tail twitch, movement of the head and legs, escape 
from stimulus, pawing, and kicking). Analgesia was 
scored on a 4-point scale as follows: 1 = deep analgesia, 
defined as markedly different responses from baseline (5 
or 6 of the observational signs disappeared); 2 = moderate 
analgesia, defined as moderately different from baseline 
value (3 or 4 observational signs disappeared); 3 = mild 
analgesia, defined as slightly different from baseline value 
(1 or 2 observational signs disappeared); and 4 = no 
analgesia, in which no response changes were observed. 
Sedation and analgesic scores of electrical stimulation 
were expressed using a 4-point scale, but analgesic score of 
pinprick was the sum (0 to 12) of the 4-point scale of the 
three sites (the right neck, right paralumbar fossa, and right 
hip). Sedation and analgesia were measured by a single 
investigator who was blinded to treatments throughout the 
experiment.
Statistical analysis
Data are expressed as the mean ± SD. Statistical analysis 
of data was performed with SPSS 17.0 software (SPSS, 
USA). The results of HR, RR, RT, CRT, and IAP were 
compared by two-way repeated measures ANOVA with 
treatment and time as independent variables. When a 
significant difference was found, Tukey’s test or paired 
t-test was applied as appropriate. Sedation and analgesic 
scores were compared by nonparametric Friedman’s test, 
followed by Wilcoxon signed ranks test. Statistical 
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Table 1. Changes of heart rate, respiratory rate, rectal temperature, and capillary refill time after xylazine (X), tramadol (T), and xylazine
plus tramadol (XT) administration
Time
(min)
Heart rate Respiratory rate Rectal temperature Capillary refill time 
X T XT X T XT X T XT X T XT
    0 34 ± 7 30 ± 8 33 ± 7 19 ± 6 17 ± 6 21 ± 8 37.8 ± 0.3 37.8 ± 0.1 37.8 ± 0.3 1.4 ± 0.2 1.5 ± 0 1.5 ± 0
    5 29 ± 6* 35 ± 6* 36 ± 12   9 ± 2* 26 ± 9* 10 ± 2* 37.9 ± 0.4* 37.9 ± 0.2 37.9 ± 0.4 1.4 ± 0.4 1.6 ± 0.2 1.5 ± 0
  10 29 ± 4* 36 ± 7* 32 ± 4 11 ± 3* 27 ± 11* 10 ± 2*    38 ± 0.4*    38 ± 0.2*    38 ± 0.4 1.4 ± 0.4 1.6 ± 0.2 1.5 ± 0
  15 28 ± 4* 36 ± 8 30 ± 4 11 ± 4* 24 ± 8* 10 ± 2*    38 ± 0.4    38 ± 0.2* 38.1 ± 0.5 1.5 ± 0 1.6 ± 0.2 1.5 ± 0
  20 28 ± 3* 37 ± 9* 29 ± 4* 12 ± 4* 25 ± 8* 10 ± 3* 37.9 ± 0.5 38.1 ± 0.2* 38.1 ± 0.6 1.5 ± 0 1.6 ± 0.2 1.5 ± 0
  25 28 ± 3* 38 ± 10* 30 ± 4 10 ± 2* 23 ± 7* 10 ± 2*    38 ± 0.5 38.1 ± 0.2* 38.1 ± 0.6 1.5 ± 0 1.5 ± 0 1.4 ± 0.2
  30 29 ± 3 38 ± 12* 30 ± 4 10 ± 1* 23 ± 8* 10 ± 3* 37.9 ± 0.5 38.2 ± 0.2* 38.1 ± 0.6 1.5 ± 0 1.5 ± 0 1.4 ± 0.2
  40 31 ± 3 35 ± 8* 29 ± 4* 10 ± 2* 22 ± 9* 10 ± 3* 37.9 ± 0.6 38.2 ± 0.2* 38.2 ± 0.6 1.5 ± 0 1.5 ± 0 1.4 ± 0.2
  50 33 ± 4 34 ± 9* 30 ± 3 11 ± 2* 23 ± 8*   9 ± 3* 37.9 ± 0.5 38.2 ± 0.3* 38.1 ± 0.5 1.5 ± 0 1.5 ± 0 1.4 ± 0.2
  60 36 ± 10 36 ± 11* 31 ± 4 11 ± 3* 20 ± 6*   9 ± 3* 37.8 ± 0.6 38.2 ± 0.3* 38.1 ± 0.5 1.5 ± 0 1.5 ± 0 1.4 ± 0.2
  75 36 ± 7 35 ± 13 32 ± 5 12 ± 4* 20 ± 8 10 ± 4* 37.9 ± 0.5 38.2 ± 0.2* 38.1 ± 0.4* 1.5 ± 0 1.5 ± 0 1.5 ± 0
  90 37 ± 8 35 ± 12 32 ± 7 14 ± 7* 20 ± 8 11 ± 4* 37.8 ± 0.6 38.1 ± 0.2*    38 ± 0.4 1.5 ± 0 1.5 ± 0 1.4 ± 0.2
105 39 ± 12 35 ± 13 32 ± 6 15 ± 8 20 ± 8 13 ± 4* 37.8 ± 0.6 38.1 ± 0.2*    38 ± 0.3 1.5 ± 0 1.5 ± 0 1.5 ± 0
120 37 ± 10 34 ± 12 33 ± 7 15 ± 7* 20 ± 7 15 ± 5* 37.8 ± 0.5 38.1 ± 0.2*    38 ± 0.3 1.5 ± 0 1.5 ± 0 1.5 ± 0
*Significantly different (p ＜ 0.05) from the baseline (time = 0). Data represents means ± SD (n = 6). 




Systolic arterial pressure Diastolic arterial pressure Mean arterial pressure
XT X T XT X T XT X T
0 122 ± 20 111 ± 28 124 ± 9   70 ± 18   61 ± 21   66 ± 10   98 ± 19   79 ± 19   95 ± 6
5 150 ± 46 119 ± 17 141 ± 7 112 ± 44   59 ± 16 103 ± 36 130 ± 42   77 ± 23 120 ± 18
10 115 ± 34 142 ± 47 123 ± 20   57 ± 24 101 ± 48   55 ± 11   91 ± 36 122 ± 44   80 ± 18
15 113 ± 38 150 ± 25* 122 ± 16   62 ± 23   87 ± 17*   80 ± 11   80 ± 25 120 ± 16*   85 ± 33
20 106 ± 45 165 ± 33 119 ± 10   63 ± 7   70 ± 13   64 ± 7   84 ± 33   92 ± 16   92 ± 11
25 110 ± 4 145 ± 30 125 ± 13   49 ± 10   84 ± 21   63 ± 17   80 ± 18 107 ± 20*   91 ± 24
30 121 ± 13 130 ± 41 129 ± 18   57 ± 24 111 ± 21*   69 ± 6   85 ± 18 108 ± 41 102 ± 22
40 115 ± 19 146 ± 9* 121 ± 24   58 ± 10   81 ± 18   72 ± 17   94 ± 29 121 ± 9*   97 ± 26
50 106 ± 20 147 ± 30 126 ± 24   44 ± 8   74 ± 7   63 ± 17   63 ± 23* 112 ± 20*   93 ± 26
60   98 ± 20 142 ± 16 124 ± 16   47 ± 16*   77 ± 6*   61 ± 14   69 ± 12* 110 ± 15*   86 ± 12
75 114 ± 6 142 ± 18 126 ± 18   51 ± 9*   86 ± 23   64 ± 18   82 ± 7 114 ± 25   94 ± 14
90 116 ± 12 138 ± 12* 123 ± 18   60 ± 9   81 ± 16   60 ± 14   88 ± 14 112 ± 12*   91 ± 17
105 119 ± 31 130 ± 16 124 ± 16   74 ± 38   78 ± 13   60 ± 10   99 ± 40 106 ± 11*   87 ± 13
120 112 ± 18 139 ± 11* 124 ± 12   59 ± 12   71 ± 15   59 ± 12   80 ± 7 105 ± 27   90 ± 18
*Significantly different (p ＜ 0.05) from the baseline (time = 0). Data represents means ± SD (n = 6).
Results
HR and RR significantly decreased from baseline with X 
and XT treatments, and significantly increased with T 
treatment (Table 1). A significant decrease in HR was more 
pronounced with X treatment (from 5∼25 min) than XT 
treatment. RT was significantly increased from baseline 
with X treatment (from 5∼10 min), T treatment (from 10
∼120 min), and XT treatment (at 75 min). CRT did not 
change significantly with any treatment. Significant 
increases in IAP were detected with X and T administered 
individually, but there was no significant change in IAP 284    Jong-pil Seo et al.
Table 3. Complications after intravenous administration of 
xylazine (X), tramadol (T), and xylazine plus tramadol (XT)
Complications X T XT
Muscle tremor 0/6 4/6 2/6
Excitement 0/6 0/6 2/6
Eye blinking rate increase 0/6 6/6 0/6
Yawn 0/6 4/6 0/6
Chewing 2/6 4/6 2/6
Tongue darting in and out 1/6 5/6 3/6
Second degree atrioventricular block 6/6 1/6 4/6
Salivation 3/6 1/6 4/6
Urination 3/6 0/6 2/6
Sweating 2/6 0/6 2/6
Data represents the number of horses showing complications, based
on the total number of horses (n = 6).
Fig. 1. Sedation score in response to intravenous administration
of xylazine (X), tramadol (T), and xylazine plus tramadol (XT).
a,b,cSignificant differences (p ＜ 0.05) from baseline (time = 0) 
value for each drug. *Significant differences (p ＜ 0.05) between
T and X. 
†Significant differences (p ＜ 0.05) between T and XT.
‡Significant differences (p ＜ 0.05) between X and XT. Sedation
score is expressed using a 4-point scale and each value represents
the means ± SD.
Fig. 2. Analgesia score with electro-stimulation in response to 
intravenous administration of xylazine (X), tramadol (T), and 
xylazine plus tramadol (XT). 
a,b,cSignificant differences (p ＜
0.05) from baseline (time = 0) value for each drug. *Significant
differences (p ＜ 0.05) between T and X. 
†Significant differences
(p ＜ 0.05) between T and XT. 
‡Significant differences (p ＜
0.05) between X and XT. Analgesic score of electrical stimulation
is expressed using a 4-point scale and each value represents the 
means ± SD.
Fig. 3. Analgesia score with pinprick in response to intravenous 
administration of xylazine (X), tramadol (T), and xylazine plus 
tramadol (XT). 
a,b,cSignificant differences (p  ＜ 0.05) from 
baseline (time = 0) value for each drug. *Significant differences
(p ＜ 0.05) between T and X. 
†Significant differences (p ＜ 0.05)
between T and XT. Significant differences between X and XT 
were not detected. Analgesic score of pinprick is expressed by 
the sum (0 to 12) of a 4-point scale of three sites (right neck, right
paralumbar fossa, and right hip) and each value represents the 
means ± SD.
noted with XT treatment (Table 2). 
X and XT produced sedation within 5 min, which lasted 
50 min for X and 75 min for XT. T treatment induced light 
sedation only at around 20 min. XT treatment showed a 
greater sedative effect than X alone (at 40, 60, and 75 min) 
(Fig. 1).
The onset of analgesia was approximately 5 min with 
both X and XT. Analgesia persisted for 50 min with 
electrical stimulation and 40 min with pinprick for X, and 
60 min for XT. T induced only light analgesia at about 10 
min with electrical stimulation. In the assessment of 
analgesia with electrical stimulation, XT treatment 
produced a greater analgesic effect than X alone at 60 min, 
while no statistically significant difference was evident 
with the pinprick method (Figs. 2 and 3). At the initial 
phase, XT treatment produced lower, but not statistically 
significant, sedative and analgesic effects with electrical 
stimulation than X alone. 
During the experiments, complications were observed in 
horses receiving X (second degree atrioventricular block, Effects of xylazine and tramadol in horses    285
salivation, urination, and sweating) and T (muscle tremor, 
eye blinking rate increase, yawn, chewing, and tongue 
darting in and out) (Table 3). Horses receiving the XT 
combination displayed these complications infrequently, 
although two horses initially displayed signs of sedation 
and then became excited approximately 3 min after drug 
administration, with sedation signs reappearing within 5 
min. In one of the latter horses, T was accidently 
administered rapidly (within 2 min). The standard procedure 
was followed for the other horse.
Discussion
When facilities are limited and/or the physical status of 
the patient is not suitable for general anesthesia, many 
surgical procedures can be performed in a standing 
position with sedation and analgesia. The combination of 
α2 agonists and opioids are most commonly used in 
standing horses for painful procedures such as laceration 
repair, flank laparotomy, and castration [10]. In this study, 
X and T were evaluated individually and in combination 
for clinical use in equine practice. X is an extensively 
studied agent and is more economical to use than other α2 
agonists, and T, a potential analgesic opioid in horses, is 
not a controlled drug in South Korea.
Unlike in humans, assessment of analgesia in animals is 
difficult [3,5]. Methods used to assess analgesia in horses 
include skin and deep muscle pinprick, pin pressing on the 
cannon bone, electrical stimulation to the coronary and/or 
fetlock region with hoof withdrawal, and skin twitching 
reflex latency with use of a heat lamp [2-4,12]. Analgesic 
effects of α2 agonists or opioids can be quantitatively 
different according to the nociceptive test used [2,4,12]. In 
this study, electrical stimulation on the left flank region and 
pinprick on the right neck, flank, and hip regions were used 
to assess analgesic effects. Results were more apparent 
with electrical stimulation than with the pinprick method. 
During the experiment, as the test with pinprick was 
repeated, horses tended to associate the approach for 
pinprick with the painful stimulus which may have 
influenced the analgesic effect results.
IV administration of X provides sedation and analgesia 
[5,6,9,12,17]; however, the duration and degree of these 
effects vary according to the drug dosage and evaluation 
method used. Complications encountered with X may 
include decreases in HR and RR, initial transient 
hypertension, wide-based stance, ataxia, second degree 
atrioventricular block, urination, and sweating. In this 
study, X produced sedation for 50 min, and analgesia for 50 
min (electrical stimulation) and 40 min (pinprick). A 
previous study reported that the IV administration of 1 
mg/kg X produced sedation for 60 min and analgesia for 40 
and 60 min as assessed by nociceptive withdrawal reflex 
and a temporal summation model, respectively [17]. Horses 
may appear well sedated by α2 agonists, but they can 
suddenly respond to painful stimulation [5,10]. This 
response usually cannot be reduced by increasing the dose 
of α2 agonists, which may pose a danger to both the patient 
and the attending veterinarian. For these reasons, opioids 
are commonly combined with α2 agonists to decrease this 
response.
T is a weak μ-opioid receptor agonist, partially antagonized 
by the opioid naloxone. It produces analgesia by opioid 
and nonopioid mechanisms, and acts as an inhibitor of the 
reuptake of monoamine neurotransmitters such as 
norepinephrine and serotonin [16,18]. Compared to other 
μ-receptor agonists such as morphine and codeine, 
respiratory depression with T is less at the recommended 
dosage [16,18]. T undergoes extensive metabolism in the 
liver, where it is converted to various metabolites [18]. In 
humans, the ratio of hepatic metabolites is affected by 
cytochrome P450 variations [7,18]. The T O-desmethyltramadol 
(M1) metabolite has a 200-fold higher affinity for the 
μ-receptor than the parent drug, and M1 is likely the 
principle reason for the analgesic effect produced by T 
[18]. T-mediate analgesia can be produced by provision of 
very low levels of M1 in horses [8,19]. This may have 
influenced the present results, given that T produced only 
mild sedation at 20 min and analgesia at 10 min with 
electrical stimulation. As previously reported, cumulative 
(0.1∼1.6 mg/kg every 20 min) and single bolus (2 mg/kg) 
injections of T did not produce sedation and analgesia, but 
horses tended to adopt a wide-based stance [4]. 
Intravenous T does not produce locomotor stimulation 
that has been observed with other opioids, but has been 
found to create other CNS excitation such as more excited 
and alert behavior, increased sensitivity to noise and 
stimulation, trembling, and head nodding [4]. Similarly, in 
this study, CNS stimulant effects were observed, included 
muscle tremor, increased rate of eye blinking, yawning, 
tongue darting in and out, and chewing motion. Increases 
of HR, RR, and RT may occur secondary to CNS 
stimulation. Muscle twitching, which as an adverse effect 
of intravenous T (2 mg/kg), can be alleviated by extending 
the time of administration to 10 min [19]; therefore, slow 
IV administration of T may help to minimize other adverse 
effects. 
Despite the lessened sedative and analgesic effects of 
intravenous T, epidural injection of T has been shown to 
produce long-lasting analgesia without CNS excitation 
and changes in motor activity and behavior [13,14]. 
To our knowledge, this is the first study to examine the 
clinical effects of a combination of an α2 agonist and T. 
Although the combination of α2 agonists and other opioids 
have been extensively studied and are widely used in 
equine practice, reflecting their increased clinical effects 
and decreased side effects [3,5,10], in this study, two 
horses in the XT treatment group became excited for 10∼286    Jong-pil Seo et al.
30 sec within 5 min after drug administration. This may 
have resulted from the CNS stimulation effect of T under 
sedation with X and warrants further study.
Although IV administration of T alone did not induce 
significant sedation and analgesia in horses, it enhanced 
the sedative and analgesic effects of X. The results suggest 
that the XT combination is useful for sedation and 
analgesia in horses. Also, it is recommended to carefully 
monitor patients when using XT in combination, due to the 
possibility of excitement following administration, 
especially in the early phase.
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